Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:07 PM EDT
133.66UNCH (UNCH)
Volume
395,302
Close
133.66quote price arrow up+3.03 (+2.32%)
Volume
800,522
52 week range
55.25 - 159.89
Loading...
  • Open132.55
  • Day High134.46
  • Day Low131.16
  • Prev Close130.63
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap12.632B
  • Shares Out94.51M
  • 10 Day Average Volume1.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change38.61

KEY STATS

  • Open132.55
  • Day High134.46
  • Day Low131.16
  • Prev Close130.63
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23
  • Market Cap12.632B
  • Shares Out94.51M
  • 10 Day Average Volume1.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change38.61

RATIOS/PROFITABILITY

  • EPS (TTM)0.08
  • P/E (TTM)1,677.04
  • Fwd P/E (NTM)47.65
  • EBITDA (TTM)-52.995M
  • ROE (TTM)2.02%
  • Revenue (TTM)1.403B
  • Gross Margin (TTM)88.18%
  • Net Margin (TTM)1.20%
  • Debt To Equity (MRQ)128.93%

EVENTS

  • Earnings Date07/31/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

 

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Bilal Arif
Executive Vice President - Strategy and Operations, Chief Technical Operations Officer
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NTRA
Natera Inc
96.98+3.26+3.48%
MEDP
Medpace Holdings Inc
392.57+1.50+0.38%
NBIX
Neurocrine Biosciences Inc
140.71+0.88+0.63%
EXAS
Exact Sciences Corp
62.07+1.53+2.53%
EXEL
Exelixis Inc
21.90-0.22-0.99%